Navigation Links
Cepheid Announces Preliminary 2008 Fourth Quarter and Full Year Revenue Results
Date:1/13/2009

SUNNYVALE, Calif., Jan. 13 /PRNewswire-FirstCall/ -- Cepheid (Nasdaq: CPHD) today announced preliminary revenue results for its 2008 fourth quarter and full year ended December 31, 2008.

Based on the company's preliminary financial results, total revenue for the fourth quarter of 2008 is expected to be approximately $38 million, with total product revenue of approximately $36 million. Total revenue for the full year ended December 31, 2008 is expected to be approximately $170 million, with total product revenue of approximately $159 million. Core clinical revenue is expected to be approximately $25 million for the fourth quarter of 2008, and approximately $91 million for the full year.

While detailed financial results are not yet available, the company expects to confirm 99 GeneXpert(R) system and 598 module placements in the fourth quarter. 45 of the GeneXpert placements and 426 modules were in North America. For the full year, GeneXpert system placements are expected to be 458 and module placements are expected to be 2,518.

Xpert(TM) MRSA test revenue is expected to be approximately $14 million for the fourth quarter of 2008, which compares to Xpert MRSA test revenue of approximately $5 million reported in the fourth quarter of 2007. For the full year, Xpert MRSA test revenue is expected to be approximately $47 million, which compares to 2007 revenue of approximately $9 million.

Fourth quarter and full year preliminary revenue results are pending finalization of the company's financial results for the quarter and year ended December 31, 2008 and accordingly are subject to change.

"While interest in our GeneXpert system and expanding menu of Xpert tests continues to grow, ongoing economic turbulence and uncertainty proved to have more of an impact on our customers th
'/>"/>

SOURCE Cepheid
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Cepheid to Webcast Upcoming Financial Presentations
2. Cepheid Accelerates Direct Sales Channel in UK With Pending Acquisition of Medical Distributor Stretton Scientific
3. Cepheid Reports Third Quarter Revenue of $44.9 Million
4. Results of United Kingdom MRSA Surveillance Program Using Cepheid GeneXpert(R) System Demonstrate Benefits of Rapid Testing
5. Cepheid Molecular Diagnostic Test for MRSA and S. aureus Categorized Moderate Complexity by FDA
6. Cepheid Schedules Fiscal 2008 Third Quarter Financial Results Announcement and Webcast
7. Cepheid Receives FDA Clearance for First On-Demand Diagnostic Test for Life-Threatening MRSA and Staphylococcus aureus From Patient Positive Blood Cultures
8. Cepheid Receives FDA Clearance for First Rapid On-Demand Molecular Diagnostic Test for MRSA and S. aureus
9. Cepheid to Webcast Upcoming Financial Presentations
10. Cepheid Introduces GeneXpert(R) Infinity-48 System at 2008 American Association of Clinical Chemistry Meeting
11. Cepheid Reports Second Quarter Revenue of $42.1 Million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... recruitment firm Slone Partners is pleased to ... Sales at Optimal Medicine, an international digital health group ... over 20 years experience in healthcare information technology client ... Dell Services Healthcare, Medsphere Systems and McKesson. , ... accomplishing the goals Optimal Medicine had for this role,” ...
(Date:3/31/2015)... 31, 2015  Biotest Pharmaceuticals Corporation (BPC), a leading ... the addition of its newest plasma collection center located ... Conway, Arkansas . The over 16,000 square foot ... March 26 th 2015 and brings the total ... "This facility represents another milestone in our ...
(Date:3/31/2015)... England , March 31, 2015 ... Singapore ,   June 30 2015   ... and medical information products and services and publishing home of ... Council has launched the Materials in Society ... presented during the 8 th International Conference on ...
(Date:3/31/2015)... , March 31, 2015  Bayer HealthCare ... Institute of Massachusetts Institute of Technology (MIT) and ... discovery. The goal of this new part of ... genetics to help create new cardiovascular therapies. ... with the Broad Institute to the area of ...
Breaking Biology Technology:Slone Partners Fills Head of Sales at Optimal Medicine 2Biotest Pharmaceuticals Corporation Announces the Opening of its Newest Plasma Collection Facility in Conway, Arkansas 2Elsevier Materials Science Council Introduces the Materials in Society Lecture Series at the International Conference on Materials for Advanced Technologies (ICMAT) 2Elsevier Materials Science Council Introduces the Materials in Society Lecture Series at the International Conference on Materials for Advanced Technologies (ICMAT) 3Bayer HealthCare Expands Collaboration with Broad Institute of MIT and Harvard to Develop Therapies for Cardiovascular Disease 2Bayer HealthCare Expands Collaboration with Broad Institute of MIT and Harvard to Develop Therapies for Cardiovascular Disease 3
... , ... --,China Yongxin Pharmaceuticals, Inc. (OTC Bulletin Board: CYXN; ,China ... of pharmaceuticals in Northeastern China, today announced it has,completed ... List. , The Chinese government ...
... , NOVATO, Calif., Nov. 30 BioMarin Pharmaceutical Inc. ... and Drug Administration (FDA) has granted orphan drug designation ... disease Lambert Eaton Myasthenic Syndrome (LEMS). 3,4-DAP has ... Also, in October 2009, the Committee for Medicinal Products ...
... , SEATTLE, ... MTA: CTIC) announced today that its new class of ... potency and activity compared to currently available platinum-based compounds ... cancer cell lines. The results were presented in ...
Cached Biology Technology:China Yongxin Pharmaceuticals Inc. to Distribute Medicines on the Essential Drug List 2China Yongxin Pharmaceuticals Inc. to Distribute Medicines on the Essential Drug List 3FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 2FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 3FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 4New Class of Platinum-Based Anti-Tumor Drugs, Bisplatinates, Demonstrates Potent Anti-Tumor Activity and Ability to Overcome Resistance to Currently Available Platinum-Based Agents 2New Class of Platinum-Based Anti-Tumor Drugs, Bisplatinates, Demonstrates Potent Anti-Tumor Activity and Ability to Overcome Resistance to Currently Available Platinum-Based Agents 3
(Date:3/23/2015)... March 23, 2015  In the 2014 fiscal year, ... conviction losses. This figure accounts for a fraction of ... The Nilson Report, exceeds $11 billion globally. The polygraph ... a crime has occurred. Investor Mark Saint Juste ... Joe Paolella partnered to administer the test ...
(Date:3/20/2015)... Markets ( http://www.researchandmarkets.com/research/rswjb4/hand_geometry ) has announced the addition ... report to their offering. This report analyzes ... report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... Annual estimates and forecasts are provided for the period 2013 ...
(Date:3/19/2015)... Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company"), ... market, announces its biometric payment technology, the Wocket® smart wallet ... on Washington DC,s Fox 5 News ... Next Great Thing", host Laura Evans calls the ... really big breakthrough in mobile payment.,  Award-winning ...
Breaking Biology News(10 mins):Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 2Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 4NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3
... is the liquid elixir that nurtures the growth of billions ... ample supply of water for farming and agriculture often means ... world, however, suffer from the opposite - the growing scarcity ... drought and desertification to climate change and climate variability, pollution, ...
... DC Scientists at the Lombardi Comprehensive Cancer Center at ... million grant to tease apart in the most comprehensive ... in breast cells in cancer development and treatment. This protein ... breast cancer and how she will fare during her treatment. ...
... 22nd, 2010-Riparian areas, ecosystems caught between the land ... temporal variability. Effectively managing and protecting riparian areas ... concepts. Fortunately, scientists are investigating new approaches in ... One of those approaches is photography. By taking ...
Cached Biology News:More water for life 2More water for life 3Lombardi receives $7.5 million grant for Breast Cancer Center for Cancer Systems Biology 2Lombardi receives $7.5 million grant for Breast Cancer Center for Cancer Systems Biology 3Learning about riparian areas from photographs 2
...
... PlusOne Silver Staining Kit, Protein, 1. ... and Dernick (1), the kit gives ... electrophoresis systems.Silver Staining Kit, Protein provides ... proteins in polyacrylamide gels in less ...
Mouse monoclonal [IFR0104] to Salmonella enteriditis ( Abpromise for all tested applications)....
Cyno macaque plasma and serum - various quantities available...
Biology Products: